PEPTIDE CORTEXThe library
← The library

MK-677

Ibutamoren; not a peptideNot a peptide · small moleculeGH Axis
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis
MechanismOrally active non-peptide ghrelin receptor agonist; included here because it is used interchangeably with GH secretagogue peptides
EffectsRaises GH and IGF-1 orally; commonly increases appetite, water retention and fasting glucose
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trial2-year RCT in adults aged 60-81 (Nass, Ann Intern Med 2008)
RouteOral
FrequencyOnce daily, 2 years
Starting25 mg once daily
EscalationNone
Target25 mg once daily

Fasting glucose rose about 0.3 mmol/L and insulin sensitivity fell; appetite increased. Not FDA-approved. Not a peptide.

Community protocol — not clinically establishedCommunity guide
RouteOral
FrequencyOnce daily, before bed
StartingConservative 10-15 mg nightly
EscalationNot a titration; three protocols instead
TargetStandard 25 mg nightly 12+ weeks; conservative 10-15 mg 8 weeks; low-dose long-term 10 mg up to 24 weeks
Cycle8-16 weeks standard; "cycling 8 on / 4 off" conservative

The guide itself says "No validated human dose".

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — Raises IGF-1 and can worsen insulin sensitivity and fluid retention; a trial in older adults recovering from hip fracture was stopped early over heart-failure signals.